

Wockhardt Limited

Investor Presentation

By

Dr. Murtaza Khorakiwala

Managing Director

Q1FY16


Safe Harbor Statement

- Except for historical information contained herein, statements in this communication, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “August”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions August constitute “forward looking statements”. These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Wockhardt Limited does not undertake any obligation to update forward looking statements to reflect events or circumstances after the date thereof.


Introduction to Wockhardt

Key Business Dynamics

Wockhardt Today



Wockhardt Today



Wockhardt Today



3 R&D Centers
worldwide

**USA / UK &
India**

Key Business Update

Key Business Update

Regulatory Update


- US FDA has completed inspection in one of the manufacturing facility in Himachal Pradesh in July, 2015 and no 483 has been issued to the company.
- US FDA's inspection of Waluj facility completed during the quarter with minor observations.
- The Company's on going efforts towards compliance measures for Chikalthana and Waluj facilities continues to be in place.
- Resumed Supplies to UK from our Chikalthana Facility.

Research Update


- Received the coveted Breakthrough discovery (QIDP) status for another NCE product WCK 4873 during the quarter. Previously 2 of its drug WCK 771 and WCK 2349 received QIDP status. QIDP status allows for fast track review by US FDA and also grants a five year extensions to the drug patents in USA. Wockhardt is the only Indian company to receive QIDP status for its NCE products.
- Got approval from US FDA for marketing 5mg/5ml of Oxycodone HCL liquid from MGP. Oxycodone is used extensively in management of pain, especially in opioid tolerant patients.
- Filed for 54 patents during the quarter taking the cumulative filings to 2322 and has been granted 26 patents during the quarter taking the cumulative patents granted to 367.

Q1FY16 Results


Sales – Growth of 15% over Q1FY15



EBITDA – Growth of 165% over Q1FY15




PAT – Growth of 470% over Q1FY15



Research – 13.3% of Sales in Q1FY16


R&D % to Sales



US Business




- **Contributes 20% of Total Revenue.**
- **Declines by 21% (26% in \$ terms) over Q1FY15.**
- **During the Q1FY16, 5 ANDA's filed & 1 approval received cumulative ANDA's pending for approval is 73.**



EU Operations


UK



UK Operations

- 1 New filing done and 1 New product launched in Q1FY16.
- UK operation Grows by 55% (grows by 59% £ terms) in Q1FY16.

Ireland



Ireland Operations


- Ireland Declines by 11% (growth of 4% in € terms) in Q1FY16.

India & Emerging Markets



- India Business Grows by 27% for Q1FY16.
- 24 new products in Q1FY16 launched in India.
- Emerging Market operations grew by 47% in Q1FY16.

India & Emerging Markets (EM)





For investor updates and communication please visit
www.wockhardt.com

For Information please contact

Arun Khatanhar

Tel.: +91 22 71596228

Akhatanhar@wockhardt.com